- Late to the CAR-T game, AstraZeneca quietly works on its own off-the-shelf therapies
- Amgen hits pause on $400M eczema bet to tweak phase 3 study
- Gilead pays out $405M for a chance to compete with Eli Lilly’s BTLA program
- Lilly 'won't be discouraged' if others fail in Alzheimer's, neuroscience chief says
- Intellia tacks on lower dose to polyneuropathy trial arm after elevated liver level in one patient
- Thinning its $11B Array of options, Pfizer drops cardiology drug after phase 3 fails futility check
- Amgen, on an M&A spree, inks $3.7B ChemoCentryx buyout to boost inflammatory disease presence
- Despite slipping sales, Siemens passes COVID testing revenue goal a quarter early
- Cigna boosts guidance as it posts $1.6B in profit for Q2
- Thermo Fisher, plugging ahead on $650M bioprocessing upgrade, unveils $76M expansion at US site
- Virtual reality tech helps separate conjoined twins in Brazil
- Over 2,000 Kaiser mental health workers plan open-ended strike
- Despite drug launch streak, Lilly posts rare sales decline as Alimta succumbs to generics
Featured Story | By James Waldron While AstraZeneca may be a major player in the oncology space, the company has been noticeably absent as the first wave of CAR-T therapies hit the market over the past five years. But movement is happening behind the scenes. read more |
| |
|---|
|
Top Stories By Nick Paul Taylor Amgen’s $400 million bet on Kyowa Kirin’s atopic dermatitis has hit a bump in the road. Weeks after starting a 570-subject phase 3 clinical trial, the partners have paused patient enrollment to make changes to the study that are unrelated to safety or efficacy. read more By Gabrielle Masson Pharma giant Gilead is handing over $405 million cash in exchange for MiroBio, a biotech developing BTLA and PD-1 autoimmune programs to go up against the likes of Big Pharmas Eli Lilly and Johnson & Johnson. MiroBio, a private U.K. biotech helmed by Novartis alum Carolin Barth, M.D., was formed to develop agonists targeting immune inhibitory receptors. read more By Annalee Armstrong Eli Lilly "won't be discouraged" if its Alzheimer's competitors flunk their critical tests, neuroscience chief Anne White has declared. The senior VP took the firm stance as Lilly announced that donanemab has been accepted for a priority review by the FDA in early onset Alzheimer's under the accelerated review pathway. read more By Max Bayer Intellia revealed a couple of pipeline changes today. Most notably, the company is adding a lower dose to the polyneuropathy arm of its ATTR trial after elevated liver enzyme levels were found in one patient 28 days after treatment. read more By Nick Paul Taylor Pfizer is axing one of the assets it picked up in the $11.4 billion takeover of Array BioPharma three years ago. After carrying out a phase 3 interim futility analysis, the Big Pharma has decided to stop work on the cardiovascular disease candidate PF-07265803. read more By Angus Liu Facing one of the biopharma industry’s steepest patent cliffs for the decade, Amgen has been on a shopping spree. The latest purchase? A $3.7 billion deal to acquire complement inhibitor developer ChemoCentryx. read more By Andrea Park Siemens' latest earnings push the year’s COVID testing total to about 1.31 billion euros, sending it past the 1.3 billion euro goal it previously set for the year—well ahead of schedule. read more By Paige Minemyer Cigna posted $1.6 billion in profit and $45.5 billion in revenue for the second quarter, according to its earnings report released Thursday. read more By Fraiser Kansteiner Thermo Fisher has completed an expansion at its dry powder media manufacturing plant in Grand Island, New York, creating “redundant capacity” and expanding the site’s production arsenal to include technology and materials used in the development and commercial production of new vaccines and biologic drugs. read more By Andrea Park The life-saving potential of VR is now on full display, as physicians in Brazil and the U.K. reported this week the success of a VR-guided surgery to separate twins who were joined at the skull. read more By Dave Muoio Scheduled to begin Aug. 15, the demonstrations center around contract negotiations and calls for expanded mental health services for Kaiser Permanente's members. The system's human resources head said the announcement was "perplexing" given how close the parties were to striking a deal just last week. read more By Eric Sagonowsky Even as Eli Lilly puts much of its energy behind a suite of new drug launches, an older cancer medicine that just tumbled off the patent cliff is proving to be a big drag on the company's financial performance. Approved in 2004 and used to treat lung cancer and mesothelioma, Alimta lost its last U.S. patent in May. read more Resources Sponsored by: Triangle Insights Group, LLC The TrialCard/Triangle Insights Group platform is uniquely positioned to support you as your asset progresses through the value chain, by integrating strategic commercialization and market access insights with comprehensive patient and provider support services. Sponsored by: Speid & Associates, Inc. The total immersion, transformative training will take place at the Harvard Club in Boston. VIRTUAL in real time is also available. Contingencies for COVID19 will apply. Register NOW for a large early bird discount www.drugstomarket.com/drugbootcamp. Sponsored by: Thermo Fisher Scientific See how integration of innovative genetic analysis techniques into drug development is driving biopharma & biotech companies ahead. Sponsored by: Nexelis Discover Nexelis’ first-hand perspective on how to develop innovative, agile solutions in vaccine efficacy testing in this exclusive e-book. Sponsored by: Catalent What is the most suitable dosage form technology for the Oral Delivery of Lipid-Based Formulations? Sponsored by: Catalent Learn how formulation development for a PFS affects manufacturing to drive the industry toward optimizing delivery of injectable products and, ultimately, improving patient care. Sponsored by: Catalent What are key considerations for intranasal delivery in the treatment of acute and chronic conditions? Sponsored by: Catalent Learn more about how the versatility of Softgel Technology helped a customer with a volatile compound. Sponsored by: Catalent How can Lipid-Based Drug Delivery System help bring poorly soluble drugs to market? Sponsored by: Catalent Carla Vozone discusses the significant trends in the OINDP segment including large molecules and novel indications, changes within CDMOs and various challenges facing the industry. Sponsored by: Catalent Did you know Catalent has newly expanded in-house capabilities spanning clinical and commercial scale manufacturing for DPIs, unit-dose, bi-dose and preserved multi-dose nasal sprays? Sponsored by: Catalent Ypsomed and Catalent Biologics experts discuss strategies for integrated PFS manufacturing and auto-injector assembly to accelerate timelines and more in this webinar. | 
